sorafenib has been researched along with anisomycin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (anisomycin) | Trials (anisomycin) | Recent Studies (post-2010) (anisomycin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,357 | 0 | 319 |
| Protein | Taxonomy | sorafenib (IC50) | anisomycin (IC50) |
|---|---|---|---|
| Glucose transporter | Leishmania mexicana | 0.225 | |
| Hexose transporter 1 | Plasmodium falciparum (malaria parasite P. falciparum) | 0.326 | |
| Solute carrier family 2, facilitated glucose transporter member 1 | Homo sapiens (human) | 0.321 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, YQ; Li, DJ; Ni, CX; Qiu, YS; Shen, FM; Zhou, CC | 1 |
1 other study(ies) available for sorafenib and anisomycin
| Article | Year |
|---|---|
Zinc supplementation ameliorates sorafenib-induced cognitive impairment through ROS/JNK signaling pathway.
Topics: Animals; Anisomycin; Apoptosis; Cell Line, Tumor; Cognitive Dysfunction; Dietary Supplements; Humans; MAP Kinase Signaling System; Mice; Neuroblastoma; Oxidative Stress; Reactive Oxygen Species; Sorafenib; Zinc | 2023 |